Submitted:
21 October 2025
Posted:
21 October 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Population and Ethics
2.2. Datasets
2.3. Dataset Harmonization and Preprocessing
2.4. ML Framework
2.4.1. ML Algorithms
2.4.2. Data Splitting, Explorative Analysis, and ML Models Training and Selection
3. Results
3.1. ML Modelling
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers (Basel). 2023;15(3):591. [CrossRef]
- Carbonara L, Casale G, De Marinis MG, Bosetti C, Valle A, Carinci P, D’andrea MR, Corli O. Adherence to ESMO guidelines on cancer pain management and their applicability to specialist palliative care centers: An observational, prospective, and multicenter study. Pain Pract. 2024 Oct 3. [CrossRef]
- van Roij J, Brom L, Youssef-El Soud M, van de Poll-Franse L, Raijmakers NJH. Social consequences of advanced cancer in patients and their informal caregivers: a qualitative study. Support Care Cancer. 2019;27(4):1187-1195. [CrossRef]
- Chen W, Huang J, Cui Z, Wang L, Dong L, Ying W, Zhang Y. The efficacy of telemedicine for pain management in patients with cancer: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2023 Feb 17;14:20406223231153097. [CrossRef]
- Buonanno P, Marra A, Iacovazzo C, Franco M, De Simone S. Telemedicine in Cancer Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Med. 2023;24(3):226-233. [CrossRef]
- Porzio G, Capela A, Giusti R, Lo Bianco F, Moro M, Ravoni G, Zułtak-Baczkowska K. Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature. Drugs Context. 2023;12:2022-11-7. [CrossRef]
- Cascella M, Marinangeli F, Vittori A, Scala C, Piccinini M, Braga A, Miceli L, Vellucci R. Open Issues and Practical Suggestions for Telemedicine in Chronic Pain. Int J Environ Res Public Health. 2021;18(23):12416. [CrossRef]
- Cascella M, Schiavo D, Grizzuti M, Romano MC, Coluccia S, Bimonte S, Cuomo A. Implementation of a Hybrid Care Model for Telemedicine-based Cancer Pain Management at the Cancer Center of Naples, Italy: A Cohort Study. In Vivo. 2023;37(1):385-392. [CrossRef]
- Cascella M, Coluccia S, Grizzuti M, Romano MC, Esposito G, Crispo A, Cuomo A. Satisfaction with Telemedicine for Cancer Pain Management: A Model of Care and Cross-Sectional Patient Satisfaction Study. Curr Oncol. 2022 Aug 4;29(8):5566-5578. [CrossRef]
- Cascella M, Innamorato MA, Natoli S, Bellini V, Piazza O, Pedone R, Giarratano A, Marinangeli F, Miceli L, Bignami EG, Vittori A. Opportunities and barriers for telemedicine in pain management: insights from a SIAARTI survey among Italian pain physicians. J Anesth Analg Crit Care. 2024 Sep 17;4(1):64. [CrossRef]
- Li YH, Li YL, Wei MY, Li GY. Innovation and challenges of artificial intelligence technology in personalized healthcare. Sci Rep. 2024;14(1):18994. [CrossRef]
- Cascella M. PainDatafor_Telemedicine_ML [Data set] Zenodo. 2022 . [CrossRef]
- Cascella, M. (2025). Telemedicine_Cancer_Pain_RUGGI [Data set]. Zenodo. [CrossRef]
- Walsh I, Fishman D, Garcia-Gasulla D, Titma T, Pollastri G; ELIXIR Machine Learning Focus Group; Harrow J, Psomopoulos FE, Tosatto SCE. DOME: recommendations for supervised machine learning validation in biology. Nat Methods. 2021;18(10):1122-1127. Erratum in: Nat Methods. 2021;18(11):1409-1410. [CrossRef]
- Luo W, Phung D, Tran T, Gupta S, Rana S, Karmakar C, Shilton A, Yearwood J, Dimitrova N, Ho TB, Venkatesh S, Berk M. Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View. J Med Internet Res. 2016;18(12):e323. [CrossRef]
- Hsu C, Chang C, Lin C. A Practical Guide to Support Vector Classification. 2003. Available from: https://api.semanticscholar.org/CorpusID:2443126.
- Cuevas FG, Schmid H. Robust Non-linear Normalization of Heterogeneous Feature Distributions with Adaptive Tanh-Estimators. Proceedings of The 27th International Conference on Artificial Intelligence and Statistics. In: Proceedings of Machine Learning Research. 2024;238:406-414 Available from https://proceedings.mlr.press/v238/guimera-cuevas24a.html.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44, 837–845.
- Coluccia, S. (2025). Telemedicine_ML_Workflow. Zenodo. [CrossRef]
- Wyte-Lake T, Cohen DJ, Williams S, Bailey SR. Balancing Access, Well-Being, and Collaboration When Considering Hybrid Care Delivery Models in Primary Care Practices with Team-Based Care. J Am Board Fam Med. 2025 Sep 15;38(3):475-489. [CrossRef]
- Cascella M, Coluccia S, Monaco F, Schiavo D, Nocerino D, Grizzuti M, Romano MC, Cuomo A. Different Machine Learning Approaches for Implementing Telehealth-Based Cancer Pain Management Strategies. J Clin Med. 2022;11(18):5484. [CrossRef]
- Nazha A, Elemento O, McWeeney S, Miles M, Haferlach T. How I read an article that uses machine learning methods. Blood Adv. 2023;7(16):4550-4554. [CrossRef]
- Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genomics. 2020;21(1):6. [CrossRef]
- Bennett MI, Kaasa S, Barke A, Korwisi B, Rief W, Treede RD; IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain. 2019 Jan;160(1):38-44. [CrossRef]
- Goncalves Leite Rocco P, Reategui-Rivera CM, Finkelstein J. Telemedicine Applications for Cancer Rehabilitation: Scoping Review. JMIR Cancer. 2024;10:e56969. [CrossRef]
- Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. [CrossRef]
- Andersen ES, Birk-Korch JB, Hansen RS, Fly LH, Röttger R, Arcani DMC, Brasen CL, Brandslund I, Madsen JS. Monitoring performance of clinical artificial intelligence in health care: a scoping review. JBI Evid Synth. 2024;22(12):2423-2446. [CrossRef]
- Chen W, Yang K, Yu Z. et al. A survey on imbalanced learning: latest research, applications and future directions. Artif Intell Rev. 2024;57:137. [CrossRef]
- Gurcan F, Soylu A. Learning from Imbalanced Data: Integration of Advanced Resampling Techniques and Machine Learning Models for Enhanced Cancer Diagnosis and Prognosis. Cancers (Basel). 2024;16(19):3417. [CrossRef]
- Araf I, Idri A, Chairi I. Cost-sensitive learning for imbalanced medical data: a review. Artif Intell Rev. 2024;57: 80. [CrossRef]
- Christopoulou SC. Machine Learning Models and Technologies for Evidence-Based Telehealth and Smart Care: A Review. BioMedInformatics. 2024; 4(1):754-779. [CrossRef]
- Contreras J, Winterfeld A, Popp J, Bocklitz T. Spectral Zones-Based SHAP/LIME: Enhancing Interpretability in Spectral Deep Learning Models Through Grouped Feature Analysis. Anal Chem. 2024 Oct 1;96(39):15588-15597. [CrossRef]
- Commission of the European Union. Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 on Artificial Intelligence (AI Act). Available from: https://artificialintelligenceact.eu/the-act/.


| Overall | Univariate analysis by Cohort | Univariate analysis by number of televisits | |||||
| Characteristic | N = 2801 | Cohort 1, N = 2261 | Cohort 2, N = 541 | p-value2 | One, N = 1431 | More, N = 1371 | p-value2 |
| Number of televisits | 0.423 | ||||||
| One | 226 (80.7%) | 111 (49.1%) | 32 (59.3%) | ||||
| More | 54 (19.3%) | 115 (50.9%) | 22 (40.7%) | ||||
| Number of televisits (numbers) 3 | |||||||
| Mean (SD) | 2.2 (2.1) | 2.2 (1.9) | 2.4 (2.8) | ||||
| Median (IQR) | 1 (1, 3) | 2 (1, 3) | 1 (1, 3) | ||||
| Cohort | 0.180 | ||||||
| Cohort 1 | 226 (80.7%) | 111 (77.6%) | 115 (83.9%) | ||||
| Cohort 2 | 54 (19.3%) | 32 (22.4%) | 22 (16.1%) | ||||
| Age | 0.333 | 0.726 | |||||
| Mean (SD) | 64.5 (12.4) | 64.1 (12.3) | 66 (12.6) | 66.5 (12.5) | 62.4 (12) | ||
| Median (IQR) | 65 (57, 74) | 65 (56, 74) | 68.5 (58.3, 75.8) | 68 (58, 76.0) | 62.5 (54, 72) | ||
| (Missing) | 5 | 5 | 0 | 2 | 3 | ||
| Sex | 0.226 | 0.073 | |||||
| Female | 140 (50%) | 109 (48.2%) | 31 (57.4%) | 79 (55.2%) | 61 (44.5%) | ||
| Male | 140 (50%) | 117 (51.8%) | 23 (42.6%) | 64 (44.8%) | 76 (55.5%) | ||
| ECOG (numbers)3 | |||||||
| Mean (SD) | 2.5 (0.7) | 2.4 (0.6) | 3 (1) | 2.5 (0.8) | 2.5 (0.7) | ||
| Median (IQR) | 2 (2, 3) | 2 (2, 3) | 3 (2, 4) | 2 (2, 3) | 2.0 (2, 3) | ||
| (Missing) | 3 | 1 | 2 | 1 | 2 | ||
| ECOG (class) | 0.019 | 0.692 | |||||
| 1-2 | 147 (53.1%) | 127 (56.4%) | 20 (38.5%) | 77 (54.2%) | 70 (51.9%) | ||
| 3-4 | 130 (46.9%) | 98 (43.6%) | 32 (61.5%) | 65 (45.8%) | 65 (48.1%) | ||
| (Missing) | 3 | 1 | 2 | 1 | 2 | ||
| Tumor site3 | |||||||
| Bladder | 18 (6.4%) | 16 (7.1%) | 2 (3.7%) | 12 (8.4%) | 6 (4.4%) | ||
| Breast | 36 (12.9%) | 30 (13.3%) | 6 (11.1%) | 13 (9.1%) | 23 (16.8%) | ||
| Endocrine | 20 (7.1%) | 11 (4.9%) | 9 (16.7%) | 6 (4.2%) | 14 (10.2%) | ||
| Gastrointestinal | 58 (20.7%) | 45 (19.9%) | 13 (24.1%) | 38 (26.6%) | 20 (14.6%) | ||
| Gynecological | 11 (3.9%) | 10 (4.4%) | 1 (1.9%) | 5 (3.5%) | 6 (4.4%) | ||
| Head/neck | 14 (5%) | 14 (6.2%) | 0 (0.0%) | 6 (4.2%) | 8 (5.8%) | ||
| Kidney | 6 (2.1%) | 6 (2.7%) | 0 (0.0%) | 1 (0.7%) | 5 (3.6%) | ||
| Lung | 39 (13.9%) | 31 (13.7%) | 8 (14.8%) | 22 (15.4%) | 17 (12.4%) | ||
| Melanoma/skin | 5 (1.8%) | 5 (2.2%) | 0 (0.0%) | 3 (2.1%) | 2 (1.5%) | ||
| Prostate | 22 (7.9%) | 16 (7.1%) | 3 (5.6%) | 11 (7.7%) | 8 (5.8%) | ||
| Soft tissue/bones | 32 (11.4%) | 22 (9.7%) | 0 (0.0%) | 9 (6.3%) | 13 (9.5%) | ||
| Others | 19 (6.8%) | 20 (8.8%) | 12 (22.2%) | 17 (11.9%) | 15 (10.9%) | ||
| Metastasis | 0.329 | 0.112 | |||||
| No | 31 (11.1%) | 23 (10.2%) | 8 (14.8%) | 20 (14.0%) | 11 (8.0%) | ||
| Yes | 249 (88.9%) | 203 (89.8%) | 46 (85.2%) | 123 (86.0%) | 126 (92.0%) | ||
| Bone metastasis | 0.002 | 0.901 | |||||
| No | 142 (50.7%) | 125 (55.3%) | 17 (31.5%) | 72 (50.3%) | 70 (51.1%) | ||
| Yes | 138 (49.3%) | 101 (44.7%) | 37 (68.5%) | 71 (49.7%) | 67 (48.9%) | ||
| BTCP | 0.083 | 0.252 | |||||
| No | 169 (60.4%) | 142 (62.8%) | 27 (50%) | 91 (63.6%) | 78 (56.9%) | ||
| Yes | 111 (39.6%) | 84 (37.2%) | 27 (50%) | 52 (36.4%) | 59 (43.1%) | ||
| Type of pain | 0.011 | 0.086 | |||||
| Nociceptive | 175 (62.7%) | 133 (59.1%) | 42 (77.8%) | 96 (67.6%) | 79 (57.7%) | ||
| Neuropathic/mixed | 104 (37.3%) | 92 (40.9%) | 12 (22.2%) | 46 (32.4%) | 58 (42.3%) | ||
| (Missing) | 1 | 1 | 0 | 1 | 0 | ||
| ROO therapy | 0.826 | 0.691 | |||||
| No | 110 (39.4%) | 88 (39.1%) | 22 (40.7%) | 58 (40.6%) | 52 (38.2%) | ||
| Yes | 169 (60.6%) | 137 (60.9%) | 32 (59.3%) | 85 (59.4%) | 84 (61.8%) | ||
| (Missing) | 1 | 1 | 0 | 0 | 1 | ||
| Hyperparameters/characteristics | Execution time to train and select (mins) | R package used for implementation | |
| RF | ntree: 20 to 100, step of 10 mtry: 3 to 6 nodesize: 9, 11, 17 |
0.86 | randomForest (v. 4.7.1.1) |
| GBM | ntree: 20 to 100, step of 10 node size: 9, 11, 17 shrink: 0.001, 0.005, and from 0.01 to 0.1, step of 0.01 |
3.39 | gbm (version 2.2.2) |
| SVM | gamma: 2 raised to the power of: from -15 to 3, step of 2 c: 2 raised to the power of: from -5 to 15, step of 2 |
3.60 | e1071 (version 1.7.14) |
| KNN | k from 2 to 5 | 0.01 | class (version 7.3.22) |
| MLP | learning rate: 0.001, 0.005, and from 0.01 to 0.19, step of 0.02 HL1: from 1 to 5 HL2: from 0 and < HL1 |
231.30 | neuralnet (version 1.44.2) |
| LR | logit link | stats (from R version 4.3.2) |
| Optimal hyperparameters | TN | FN | FP | TP | F1-score | Accuracy | AUC-ROC | |
| RF | ntree: 70; mtry: 3; node size: 9 | 19 | 19 | 15 | 19 | 0.43 | 0.49 (95%CI: 0.36, 0.61) | 0.43 |
| GBM | ntree: 80; node size: 11; shrink: 0.02 |
17 | 19 | 17 | 13 | 0.42 | 0.46 (0.33, 0.67) | 0.42 |
| SVM | gamma: 2; c: 0.125 | 18 | 14 | 16 | 18 | 0.55 | 0.55 (0.42, 0.61) | 0.55 |
| KNN | k: 3 | 18 | 18 | 16 | 14 | 0.45 | 0.48 (0.36, 0.61) | 0.45 |
| MLP | learning rate: 0.05; HL1: 4; HL2: 3 | 0 | 0 | 34 | 32 | 0.65 | 0.48 (0.36, 0.61) | 0.65 |
| LR | 20 | 18 | 14 | 14 | 0.47 | 0.52 (0.39, 0.64) | 0.47 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).